undamentalytics Newsletter
Sign in

Biontech SE (BNTX) stock

Add to watchlist

Add holding +

NASDAQ: BNTX Nasdaq Biotechnology Next results ~November 3, 2026

B Fundamentals grade

Biontech SE is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$150

Cash-flow model

Base case. Range ~$120–$180 across our lower- and higher-growth cases (-1%–9% a year).

Price vs value

Undervalued

The price is below our entire value range; our base value is 66% above it.

Price used: $87.53, November 2, 2026

Biontech SE valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 2 selling0 purchases and 27 sales by directors and officers, last 12 monthsInsider trades
  • Funds132 adding, 100 cuttingOf 40 active managers that changed their stake, 22 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Biontech SE files

Where Biontech SE stands after its latest Filing

Revenue for the twelve months was $3.24bn, up 9.0% on a year earlier, against a decline of 27.9% a quarter earlier. Free-cash-flow margin rose to 9.8% from 4.0% a year earlier. Operating margin narrowed to -49.0% from 80.5%. Against its peers on growth, profitability, cash generation and balance sheet, it grades B. It passes 2 of our 3 financial-health checks. Our cash-flow model value is $145 a share, against a share price of $88.17. At that price, our model says the market is pricing in cash flow shrinking about 8.7% a year for five years, slower than the 42.6% a year revenue growth it has delivered.

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 3, 2026 (estimated)

Biontech SE's trailing-twelve-month revenue grew 9.0% year on year, with a free-cash-flow margin of 9.8%. Where it stands out: stock pay as % of revenue of 3.7% ranks 26 of 179 biotechnology companies we cover.

Our discounted-cash-flow model values the business at ~$150 per share in the base case (~$120–$180 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Revenue growth accelerating: TTM revenue growth rose to 9.0% (+36.9pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Priced below our value. The share price of $87.53 is 66% below our value per share of $150.
  • Growth speeding up. The growth rate is 36.9 points higher than a quarter earlier.
  • Net cash. Cash exceeds long-term debt by $9.0bn.

Things to watch

  • Loss-making. Operating margin is -49.0%: costs exceed revenue.
  • Insiders selling. 2 insiders sold $90M of stock over the past 365 days and none bought (100% under pre-set trading plans).
  • Gross margin slipping. Gross margin is down 2.7 points on a year ago.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 4 of the last four quarters.

Latest results

Earnings per share
-$2.22 against an average estimate of -$2.08: missed by 6.8%
Next report
November 3, 2026

Biontech SE's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-0.7%
  • 1 week+0.8%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$3.2B
Operating margin
-49.0%
Net margin
-39.6%
EPS (TTM, diluted)
$-5.31

Growth

Revenue growth
+9.0%
Change in growth rate
+36.9 pts
Share count change
+0.5%

Cash

Free cash flow (TTM)
$318M
FCF margin
9.8%
Stock pay % of revenue
3.7%

News & updates

Updated November 2, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Insider trade
  2. Insider trade
  3. Insider trade
  4. Insider trade
  5. Insider trade
  6. Insider trade
  7. Insider trade
  8. Insider trade
  9. Insider trade
  10. Insider trade
  11. Insider trade
  12. Insider trade
  13. Insider trade
  14. Insider trade
  15. Insider trade
  16. Insider trade
  17. Insider trade
  18. Insider trade
  19. Insider trade
  20. Insider trade

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Biontech SE valuation models and calculator

What the price is pricing in

The share price implies cash flow shrinking about 8.8% a year for five years.That is slower than the 42.6% a year revenue growth Biontech SE has delivered.

  • Priced in-8.8%
  • Last 12 months9.0%
  • 3 years a year-43.8%
  • 5 years a year42.6%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($87.80, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Buy12-month view
12-month price target
~$150
Price used
$87.80close November 3, 2026
Implied change
▲ +65%
Uncertainty
Low

How we got here: a discounted-cash-flow model of Biontech SE's free cash flow after stock-based pay with after-tax interest added back ($1.5B, FY2025 Q4 TTM), growing 4% a year for five years and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$120–~$180 ; that spread sets a 15% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Biontech SE's free cash flow after stock-based pay ( $1.5B, FY2025 Q4 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Biontech SE as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$150 ~$120–$180 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: return on equity above 40%: buybacks or intangibles make book value too small an anchor
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$230 ~$200–$260 Included
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$170 ~$150–$230 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Biontech SE with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −12%
  • Revenue growth 5 points higher ▲ +15%
  • Free-cash-flow margin 1 point lower ▼ −5%
  • Discount rate 1 point higher ▼ −7%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $121$151$191$244$313$402
8.5% $101$123$152$189$239$302
10% $89$106$128$157$194$242

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 3, 2026, before the open.

Analysts' consensus

No analyst estimates are published for Biontech SE: too few analysts cover it.

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$2.08 −$2.22 −6.8%
Mar 2026 −$1.92 −$1.95 −1.6%
Dec 2025 −$0.25 −$0.33 −30.4%
Sept 2025 $0.10 −$0.12 −220.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

21 analysts, Nov 2026
Buy1467%
Hold733%
Sell00%

Monthly trend

  1. Nov 202613721
  2. Oct 202613520
  3. Sep 202614420

Counts of recommendations published by analysts covering Biontech SE, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
3.4%
of tradable shares
Days to cover
2.35
at average volume
Short interest, 1 month
−2%
to October 15, 2026
Held by institutions
20%
of shares
Held by insiders
57.2%
of shares
Employees
7,807
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Price behaviour

52-week range
Not enough history
From 52-week high
—
vs 50-day average
—
vs 200-day average
—
Volatility (1 year)
—
Beta vs S&P 500
—

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Options strategies

All options ideas

How Biontech SE’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Implied vs realised volatility

Not enough history

There is not enough price history to measure realised volatility.

  • Calls are priced 3 points richer than puts (25-delta): demand for upside is high, which favours selling calls over puts.
  • Why: not enough price history to measure realised volatility.

Our rule for “rich”: implied at least 1.2× 60-day realised (beyond measurement noise), above 1-year realised (not just a calm spell), and in the top 20% of our coverage that day. Never with results inside the option’s life. These are our conventions, built on research showing option prices usually imply more movement than follows, most when the gap is wide. How we judge this.

Cash-secured put

Not offered: fundamentals grade B (needs B+ or better).

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

Covered call

Not offered: no liquid call at or above our price target — the model says the upside is worth more than any listed strike.

For holders: sell a call at a strike at or above our fair value, so the shares are only sold at a price the model calls full value.

Collar

Not offered: the shares trade below our fair value: a collar caps upside the model expects.

For holders of a stock trading at or above our fair value: buy a put for a floor and sell a call to pay for it.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

Biontech SE in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Biontech SE
$0 $10B $20B $30B FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 Revenue (TTM), FY17 Q4: $69.6M Revenue (TTM), FY18 Q4: $150.8M Revenue (TTM), FY19 Q4: $121.6M Revenue (TTM), FY20 Q4: $550.3M Revenue (TTM), FY21 Q4: $22.5B Revenue (TTM), FY22 Q4: $18.2B Revenue (TTM), FY23 Q4: $4.1B Revenue (TTM), FY24 Q4: $3B Revenue (TTM), FY25 Q4: $3.2B $3.2B

Source: SEC EDGAR filings. Retrieved November 2, 2026.

View chart data
Period Revenue (TTM)
FY17 Q4 $69.6M
FY18 Q4 $150.8M
FY19 Q4 $121.6M
FY20 Q4 $550.3M
FY21 Q4 $22.5B
FY22 Q4 $18.2B
FY23 Q4 $4.1B
FY24 Q4 $3B
FY25 Q4 $3.2B
Revenue growth, TTM YoY Biontech SE
-2000% 0% 2000% 4000% FY18 Q4 FY20 Q4 FY22 Q4 FY25 Q4 Revenue growth, TTM YoY, FY18 Q4: 116.6% Revenue growth, TTM YoY, FY19 Q4: -19.4% Revenue growth, TTM YoY, FY20 Q4: 352.7% Revenue growth, TTM YoY, FY21 Q4: 3979.5% Revenue growth, TTM YoY, FY22 Q4: -18.8% Revenue growth, TTM YoY, FY23 Q4: -77.3% Revenue growth, TTM YoY, FY24 Q4: -27.9% Revenue growth, TTM YoY, FY25 Q4: 9.0% 9.0%

Source: SEC EDGAR filings. Retrieved November 2, 2026.

View chart data
Period Revenue growth, TTM YoY
FY18 Q4 116.6%
FY19 Q4 -19.4%
FY20 Q4 352.7%
FY21 Q4 3979.5%
FY22 Q4 -18.8%
FY23 Q4 -77.3%
FY24 Q4 -27.9%
FY25 Q4 9.0%
Operating margin (TTM) Biontech SE
-200% -100% 0% 100% FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 Operating margin (TTM), FY17 Q4: -99.5% Operating margin (TTM), FY18 Q4: -42.2% Operating margin (TTM), FY19 Q4: -167.1% Operating margin (TTM), FY20 Q4: -17.1% Operating margin (TTM), FY21 Q4: 80.5% Operating margin (TTM), FY22 Q4: 73.0% Operating margin (TTM), FY23 Q4: 18.1% Operating margin (TTM), FY24 Q4: -47.8% Operating margin (TTM), FY25 Q4: -49.0% -49.0%

Source: SEC EDGAR filings. Retrieved November 2, 2026.

View chart data
Period Operating margin (TTM)
FY17 Q4 -99.5%
FY18 Q4 -42.2%
FY19 Q4 -167.1%
FY20 Q4 -17.1%
FY21 Q4 80.5%
FY22 Q4 73.0%
FY23 Q4 18.1%
FY24 Q4 -47.8%
FY25 Q4 -49.0%
FCF margin (TTM) Biontech SE
-300% -200% -100% 0% 100% 200% FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 FCF margin (TTM), FY17 Q4: -124.8% FCF margin (TTM), FY18 Q4: -69.6% FCF margin (TTM), FY19 Q4: -218.3% FCF margin (TTM), FY20 Q4: -16.5% FCF margin (TTM), FY21 Q4: 4.0% FCF margin (TTM), FY22 Q4: 76.5% FCF margin (TTM), FY23 Q4: 134.1% FCF margin (TTM), FY24 Q4: -2.9% FCF margin (TTM), FY25 Q4: 9.8% 9.8%

Source: SEC EDGAR filings. Retrieved November 2, 2026.

View chart data
Period FCF margin (TTM)
FY17 Q4 -124.8%
FY18 Q4 -69.6%
FY19 Q4 -218.3%
FY20 Q4 -16.5%
FY21 Q4 4.0%
FY22 Q4 76.5%
FY23 Q4 134.1%
FY24 Q4 -2.9%
FY25 Q4 9.8%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 20-F, 20-F/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025
Income
Revenue 0.1 0.2 0.1 0.6 22.5 18.2 4.1 3.0 3.2
Gross profit 0.1 0.1 0.1 0.5 19.0 15.1 3.5 2.4 2.5
Operating income −0.1 −0.1 −0.2 −0.1 18.1 13.3 0.7 −1.4 −1.6
Net income −0.1 −0.1 −0.2 0.0 12.2 9.9 1.0 −0.7 −1.3
Diluted EPS — — −$0.95 $0.07 $46.88 $39.79 $4.14 −$3.00 −$5.31
Growth (year on year)
Revenue — +116.6% −19.4% +352.7% +>999% −18.8% −77.3% −27.9% +9.0%
Operating income — — — — — −26.3% −94.4% −290.4% —
Net income — — — — +>999% −18.4% −89.9% −171.5% —
Diluted EPS — — — — +>999% −15.1% −89.6% −172.3% —
Margins
Gross margin 84.9% 89.3% 84.0% 87.7% 84.7% 82.7% 84.3% 80.3% 77.6%
Operating margin −99.5% −42.2% −167.1% −17.1% 80.5% 73.0% 18.1% −47.8% −49.0%
Net margin −139.1% −37.6% −164.9% 3.2% 54.2% 54.5% 24.4% −24.2% −39.6%
Free-cash-flow margin −124.8% −69.6% −218.3% −16.5% 4.0% 76.5% 134.1% −2.9% 9.8%
Cash flow
Cash from operations −0.1 −0.1 −0.2 −0.0 1.1 14.3 5.8 0.2 0.5
Capital spending 0.0 0.0 0.0 0.1 0.2 0.3 0.3 0.3 0.2
Free cash flow −0.1 −0.1 −0.3 −0.1 0.9 14.0 5.5 −0.1 0.3
Stock-based pay 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1
Free cash flow after stock pay −0.1 −0.1 −0.3 −0.1 0.8 13.8 5.5 −0.2 0.2
Balance sheet
Cash 0.2 0.5 0.6 1.5 1.9 14.8 12.9 10.1 9.0
Total debt 0.0 0.0 0.1 0.3 0.3 — 0.0 0.0 0.0
Net debt (negative = net cash) −0.2 −0.5 −0.5 −1.2 −1.6 −14.8 −12.9 −10.1 −9.0
Diluted shares 167m 191m 211,500m 248,500m 260m 250m 243m 240m 242m
Returned to shareholders
Dividends — — — 0.0 0.0 0.5 0.0 0.0 —
Total returned — — — 0.0 0.0 0.5 0.0 0.0 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 3 checks passed · December 31, 2025
What it owns · $25.8bn
Short-term assets $18.9bnLonger-term assets $6.9bn
What it owes, and who funded it · $25.8bn
Short-term liabilities $2.5bnLonger-term liabilities $730mShareholders' equity $22.6bn
  • Short-term assets cover short-term liabilities $18.9bn of assets due within a year against $2.5bn of liabilities due within a year.
  • Short-term assets cover long-term liabilities $18.9bn short-term assets against $730m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$1.6bn against $16m of interest.

From Biontech SE's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Dividends (TTM)
$0
Returned to shareholders
0%
of free cash flow
Diluted share count
+0.5%
year over year
Total shareholder yield
0.0%
dividends 0.0% + buybacks 0.0% of market value
R&D spending
73.3%
of revenue
Days sales outstanding
122 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated BNTX UTHR BMRN NBIX NTRA ARGX Median
Revenue, last 12 months $3.2bn $3.2bn $3.4bn $3.7bn $2.7bn $4.2bn $56m
Revenue growth, last 12 months 9.0% 2.5% 11.2% 38.0% 37.8% 89.9% 12.6%
Revenue growth, 3-year average — 14.3% 15.1% 27.5% 42.7% — 13.7%
Revenue growth, latest quarter — −1.9% 19.9% 41.2% 37.7% — 10.2%
Gross margin 77.6% 86.1% 76.1% 98.2% 42.0% 89.1% 82.9%
Operating margin −49.0% 44.4% 4.4% 24.0% −10.7% 25.4% −189.4%
Operating margin, 3-year average −22.6% 46.6% 13.3% 23.4% −16.2% — −363.5%
Net margin −39.6% 41.6% 2.1% 19.0% −7.1% 31.1% −169.8%
Cash from operations / revenue 15.9% 53.4% 25.2% 28.8% 8.4% 16.5% −168.0%
Free-cash-flow margin 9.8% 34.6% 21.7% 28.1% 3.1% 16.4% −162.4%
Free-cash-flow margin, 3-year average −37.0% 34.3% 17.8% 23.3% 0.2% — −310.0%
Stock pay / revenue 3.7% 4.9% 6.3% 6.4% 14.1% 6.0% 20.0%
Change in share count 0.5% −3.1% 1.0% 1.9% 6.5% 1.3% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 9.0% 12.6% 96 of 172
Change in growth rate Growth +36.9pp -0.1pp 30 of 172
Gross margin Profitability 77.6% 82.4% 45 of 75
Operating margin Profitability -49.0% -189.4% 63 of 175
Net margin Profitability -39.6% -157.3% 58 of 180
Free-cash-flow margin Cash generation 9.8% -145.4% 33 of 176
Stock pay as % of revenue Cash generation 3.7% 19.2% 26 of 179
Change in share count Balance sheet 0.5% 7.9% 28 of 156
Days sales outstanding Balance sheet 122 days 75 days 74 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$4.4B
Institutions reporting
281
Shares held vs prior quarter
▼ 0.3%
Positions opened / closed
39 / 29

Top buyers and sellers, Q2 2026: 132 institutions bought and 100 sold ; the biggest buyer was FMR LLC (+1.9M shares) and the biggest seller T. Rowe Price Investment Management, Inc (−3.8M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
FMR LLC $705M 7.6M 16.0% ▲ 32.6%
Primecap Management Co $351M 3.8M 8.0% ▼ 0.6%
Dodge & Cox $342M 3.7M 7.8% 0.0%
Flossbach Von Storch Se $207M 2.2M 4.7% ▼ 39.5%
T. Rowe Price Investment Management, Inc. $192M 2.1M 4.4% ▼ 64.7%
Blackrock, Inc. $173M 1.9M 3.9% ▲ 11.9%
Temasek Holdings (Private) Ltd $140M 1.5M 3.2% 0.0%
BNP Paribas Financial Markets $123M 1.3M 2.8% ▼ 20.1%
Logos Global Management LP $94.4M 1.0M 2.1% New
Gsk PLC $82.8M 890K 1.9% 0.0%
Assenagon Asset Management S.A. $78.8M 847K 1.8% New
First Trust Advisors LP $73.6M 791K 1.7% ▼ 5.8%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Biontech SE's complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $89.8M 27 trades by 2 insiders · 100% under pre-set plans
Net ▼ $89.8M net selling
Insider Date Trade Shares Price Value
Sahin Ugur Chief Executive Officer October 9, 2026 Sell pre-set plan 36,209 $95.37 $3.5M
Sahin Ugur Chief Executive Officer October 8, 2026 Sell pre-set plan 27,000 $92.31 $2.5M
Sahin Ugur Chief Executive Officer October 7, 2026 Sell pre-set plan 24,000 $95.86 $2.3M
Sahin Ugur Chief Executive Officer October 6, 2026 Sell pre-set plan 21,000 $96.81 $2M
Sahin Ugur Chief Executive Officer October 5, 2026 Sell pre-set plan 72,000 $97.23 $7M
Sahin Ugur Chief Executive Officer October 2, 2026 Sell pre-set plan 17,000 $96.72 $1.6M
Sahin Ugur Chief Executive Officer October 1, 2026 Sell pre-set plan 17,000 $97.46 $1.7M
Sahin Ugur Chief Executive Officer September 30, 2026 Sell pre-set plan 32,000 $98.12 $3.1M
Sahin Ugur Chief Executive Officer September 29, 2026 Sell pre-set plan 34,000 $98.26 $3.3M
Sahin Ugur Chief Executive Officer September 28, 2026 Sell pre-set plan 34,000 $98.47 $3.3M
Sahin Ugur Chief Executive Officer September 25, 2026 Sell pre-set plan 27,000 $98.69 $2.7M
Sahin Ugur Chief Executive Officer September 24, 2026 Sell pre-set plan 39,000 $98.99 $3.9M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 8 trades and filings

No trades in Biontech SE disclosed in the last 12 months; 8 earlier trades on record.

  • Val T. Hoyle(D-OR 4):Sale (full), $1,001 - $15,000, traded August 7, 2025, filed September 12, 2025
  • Josh Gottheimer(D-NJ 5):Sale (full), $1,001 - $15,000, traded September 3, 2024, filed October 3, 2024
  • Josh Gottheimer(D-NJ 5):Sale (partial), $1,001 - $15,000, traded August 30, 2024, filed September 11, 2024

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

  • 6-K 6-K
  • 6-K 6-K
  • 6-K 6-K
  • 6-K 6-K
  • 6-K 6-K
  • 6-K 6-K
  • 6-K 6-K
  • 6-K 6-K

Data status

When each part of this page on Biontech SE was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Biontech SE in brief

What does Biontech SE do?
Biontech SE is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Biontech SE's stock ticker?
Biontech SE trades under the ticker BNTX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Biontech SE's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Biontech SE reported revenue of $3.2B, 9.0% higher than a year earlier, according to its SEC filings.
What is Biontech SE's free cash flow?
Biontech SE's free-cash-flow margin is 9.8% of revenue over the trailing twelve months, ranking 33 of the 176 biotechnology companies we cover.
What is Biontech SE's fair value (intrinsic value) per share?
Our discounted-cash-flow model of Biontech SE's free cash flow after stock-based pay gives ~$150 per share in the base case, and ~$120–$180 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Biontech SE's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are FMR LLC, Primecap Management Co and Dodge & Cox. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Does Biontech SE pay a dividend?
Biontech SE reported no dividend payments in its trailing twelve months of filings.
Who are Biontech SE's competitors?
In our Biotechnology peer group, the companies closest to Biontech SE are United Therapeutics Corp, Biomarin Pharmaceutical Inc, Neurocrine Biosciences Inc, Natera, Inc. and Argenx SE. The side-by-side comparison below sets their revenue, margins and growth against Biontech SE's.
Are insiders buying or selling Biontech SE stock?
Over the last 12 months, Biontech SE's directors and officers reported 0 open-market purchases and 27 sales on Form 4. The insider trading page charts every trade.
When is Biontech SE's next earnings date?
Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Biontech SE announces its own schedule.